Pulmonary Arterial Hypertension

Latest News

For Patients with PAH, HRQoL Impacts are Significant and Complex
For Patients with PAH, HRQoL Impacts are Significant and Complex

May 9th 2024

Research shows health-related quality of life is impacted in major ways by pulmonary arterial hypertension, but a solution to the problem—and the disease itself—has proven elusive.

FDA Updates for Week of March 25: Two Approvals for PAH
FDA Updates for Week of March 25: Two Approvals for PAH

March 30th 2024

 FDA Approves Merck’s Drug for Pulmonary Arterial Hypertension
FDA Approves Merck’s Drug for Pulmonary Arterial Hypertension

March 26th 2024

FDA Approves Combination Therapy for PAH
FDA Approves Combination Therapy for PAH

March 25th 2024

Silicone Particles in Product Leads to Recall of Treprostinil
Silicone Particles in Product Leads to Recall of Treprostinil

March 14th 2024

© 2024 MJH Life Sciences

All rights reserved.